David g. Morgan, ph. D. 1 Jan 2009




Скачать 154.23 Kb.
НазваниеDavid g. Morgan, ph. D. 1 Jan 2009
страница3/4
Дата17.10.2012
Размер154.23 Kb.
ТипДокументы
1   2   3   4

Invited Presentations (from 1996 on)


April 22, 1996. Amyloid, Astrocytes and Aging in Rat Brain. Mayo Clinic, Jacksonville FL.


April 23, 1996. Neuroanatomy of Presenilins in Rat Brain. Mayo Clinic, Jacksonville, FL.


July 10, 1996. Amyloid and presenilins in rat brain. Wyeth Ayerst Research, Princeton, NJ.


March 7, 1997. Expression of presenilins in rat and transgenic mouse brain. Biochemistry and Molecular Biology, University of South Florida, Tampa, FL


May 9, 1997. The genetics of Alzheimer's dementia. Florida Association of Geriatric Care Givers, Fort Lauderdale, FL


August 28, 1997. Behavioral and Anatomical effects of Presenilin Mutations in Transgenic mice. Neurology Grand Rounds, USF Tampa FL


November 19, 1997. Aβ deposition in doubly transgenic mice. Dept of Anatomy, University of South Florida, Tampa FL


February 24, 1998, Alzheimer's Disease. As part of Successful Aging, 1998 by the USF Institute On Aging, Ruth Eckerd hall, Clearwater FL


July 29, 1998. Is Aβ Amyloid Neurotoxic in Transgenic Mice?. GRECC University of Florida, Gainesville FL


January 8, 1999. Are Aβ Deposits Neurotoxic in Transgenic Mice? The Role of Complement. Astra -Arcus Inc., Worcester MA


December 16, 1999. Emergence of memory deficits in APP/PS1 transgenic mice. AstraZeneca, Worcester MA


January 8, 2000. Correlation of amyloid with behavior in transgenic mice. Winter Conference on the Neurobiology of Memory, Park City UT


February 22, 2000. Animal models of Alzheimer's disease as an approach to therapeutics. USF Institute on Aging Public Information Program, Clearwater FL


March 24, 2000. Trangenic mouse models of Alzheimers Disease. Correlations between amyloid and behavior. Dept, of Biology, USF, Tampa FL


June 23 , 2000. Vaccination NSAIDS and microglia in doubly transgenic mice. Mayo Clinic, Jacksonville, FL


July 8. 2000. Aß vaccination protects from memory loss in APP+PS1 transgenic mice. 7th International Conference on Alzheimer's Disease, Washington, DC


October 23, 2000 Behavioral endpoints in transgenic mouse models of Alzheimer's disease: Effects of vaccination. Elan Pharmaceuticals, South San Francisco, CA


October 31, 2000. Pathobiology of Alzheimer's disease and rational design of therapeutics. American Osteopathic Association, Invited Lecture, Orlando, FL.


1 March 2001. Modulation of amyloid deposition in a transgenic mouse model of Alzheimer's disease. Oklahoma Medical Research Foundation, Oklahoma City, OK.


2 April 2001. Alzheimer's Disease. Pharmacological Approaches. Haley Veteran's Administration Hospital, Tampa FL


3 April 2001. Research Update. Alzheimer's Disease Vaccine. Alzheimer's Association Convention, Tampa Bay Chapter, Tampa FL.


20 April, 2001. Anti-inflammatory drugs in a mouse model of amyloid deposition. AstraZeneca Inc, Wilmington DE


7 May, 2001. Update on Alzheimer's Disease. National Association of Retired Federal Employees Convention, Tampa FL


11 May, 2001. NCX 2216 reduces amyloid plaque load in a transgenic model of Alzheimer's disease, Nitric Oxide and Cox Satellite Symposium, Capri, Italy


14 May 2001. Microglial activation in a mouse model of amyloid deposition. University of Milano-Bicocca, Milan, Italy


21 May, 2001. The new pharmacology of Alzheimer's disease. Alzheimer's Association Tampa Chapter Meeting, Brandon FL


4 June 2001. The effect of dietary macro- and micro-nutrients on amyloid pathology in a transgenic model of Alzheimer's disease. American Aging Association, Madison WI


7 June 2001. What's in the future for Alzheimer's disease treatment? The vaccine and other research updates. USF Geriatric Institute, Tampa FL


15 August 2001. A transgenic model of amyloid deposition. Joy McCann Culverhouse Airway Disease Center Molecular Medicine Seminar, USF Internal Medicine, Tampa FL.


24 September 2001. Cognitive improvements after beta amyloid immunization in a mouse model of plaque formation. Laura Chalk Rowles Lecture, McGill Center for Studies on Aging, Montreal, Canada.


29 September 2001. Amyloid vaccination in a transgenic mouse model of amyloid deposition. Dept. of Neuroscience, University of Florida, Gainesville, FL.


5 October 2001. Neurodegenerative Disease- Vaccines for Alzheimer's Disease. Invited presentation Southeastern Pharmacological Society meeting, Clearwater FL.


1 November 2001. "Bap"tists versus "Tau"ists: Competing Theories about Alzheimer's Disease. Phi Beta Kappa Association, Tampa, FL


9 November 2001. The role of transgenic mouse models of amyloid deposition in Alzheimer's disease research. Invited Speaker at Brain Aging, Identifying accelerators and brakes, San Diego CA.


14 November 2001. Effects of NCX-2216 in APP+PS1 transgenic mice. GlaxoSmithKlein CEDD, San Diego, CA


11 December 2001. Functional consequences of ab immunization in the APP+PS1 transgenic mouse . American College of NeuroPsychopharmacology Meeting Kona, HI.


15 January 2002. Transgenic models of amyloid deposition; Vaccines, NSAIDs and gene expression. Winter Conference on Learning and Memory. Park City, UT


18 January 2002. Pharmacological modulation of a mouse model of amyloid deposition. Dept of Biochemistry and Molecular Biology, U South Florida, Tampa FL


12 February 2002. Update on transgenic models of amyloid deposition. AstraZeneca, Wilmington DE


15 February 2002. The role of transgenic mouse models of amyloid deposition in Alzheimer's disease research. Chicago Chapter Society for Neuroscience Annual Meeting. Chicago IL


26 February 2002. Phenotypic modification of an mouse model of amyloid deposition. Wyeth-Ayerst Laboratories, Princeton NJ.


6 April, 2002. Aß Vaccination in an APP+PS1 Transgenic Mouse Model of Amyloid Deposition. Springfield Symposium on Therapies for Alzheimer Disease, Geneva, Switzerland.


2 May 2002. Protection from Memory Deficits by Amyloid Vaccines in a Transgenic Mouse Model of Amyloid Deposition. Army Institute of Research Basic Aspects of Vaccines Symposium, Bethesda MD


8 June 2002. Inflammatory mechanisms in brain aging: Possible sites for intervention. American Aging Association Meeting, San Diego, CA


25 June 2002. Modulation of amyloid deposition and learning in an APP+PS1 transgenic model by Aß vaccination and a Nitro-NSAID, SRI symposium on Neurodegeneration, Princeton, NJ


9 July 2002.Vaccines, NSAIDs and Microglial Activation in a Mouse Model of Amyloid Deposition. Eli Lilly Inc, Indianapolis IN


23 July 2002. Clearance of amyloid by vaccination. Invited symposium presentation, 8th International Conference on Alzheimer's Disease, Stockholm Sweden


9 September 2002. Immunotherapeutic approaches to a transgenic mouse model of amyloid deposition. University of Nebraska, Omaha NE


22 October, 2002. Lunch with a Scholar: Update on Alzheimer's Disease. Northern Trust Bank, Indian Rocks Beach FL


30 January 2003. Is Excess Aß Amyloid A Necessary Condition for Alzheimer's Disease? Winter Conference on Brain Research, Snowbird UT.


24 February 2003. Curing dementia in an Alzheimer's Mouse. Voices from the Inside, USF Institute on Aging, Tampa FL.


11 May 2003. Synaptic gene expression in APP+PS1 transgenic mice. 6th International Conference on AD/PD, Seville, Spain


16 June 2003. Amyloid Immunotherapy, Microglia and Memory in APP+PS1 Transgenic Mice, University of California, Irvine, CA


17 June 2003. Making memories in mouse models of amyloid deposition. University of Southern California, Los Angeles, CA


27 July 2003. Are Aß Vaccines the Answer to Treating Alzheimer's Disease? Challenging Views, Cincinnati, OH


16 September 2003. Evidence fo Anti-Aß Immunotherapy in Alzheimer's Disease. Neurology Grand Rounds, Duke University, Durham NC


17 September 2003. Microglia Molecules and Memory in a Mouse Model of Amyloid Deposition. Ortho-McNeil lecture in Alzheimer's Research. Duke University, Durham, NC


11 November 2003. Is Inflammation Beneficial or Detrimental in Neurodegenerative Disease? Neurological Disease Foundation, New Orleans, LA.


10 December 2003. Vaccination and NSAIDs in AD models. Glial Inflammation in Disease NIH

Workshop. Washington, DC


16 December 2003. Vaccines as therapy for Alzheimer's dementia. Bristol Myers Squibb

Consultants Panel, New York, NY


5 January 2004. Treatment approaches to curing Alzheimer’s disease. AFAR symposium, Ocala

FL


5 February 2004. New treatments for Alzheimer's Disease. State of Florida Alzheimer's Summit

Tallahassee, FL


23 February 2004. Mechanisms of amyloid–associated memory dysfunction. Winter Conference on Neural Plasticity, St. Lucia, West Indies.


14 May 2004. Synaptic changes in APP+PS1 transgenic mouse models of amyloid deposition. Stereology Workshop, North Captiva Island, FL.


18 May 2004. Anti-amyloid Immunotherapy for Alzheimer's Disease: Effects on a Transgenic Model. Burnham Institute, La Jolla, CA.


19 May 2004. Anti-amyloid immunotherapy effects on learning and memory in transgenic mouse models of amyloid deposition. Dept. of Neurosciences, University of California, San Diego, CA.


19 August 2004. Prospects for Success of Anti-Aß Immunotherapy. Lessons From
Mouse Models of Amyloid Deposition. Pfizer Inc. Groton CT


23 August 2004. Immunochemical approaches to reducing brain amyloid. Merck Inc, West Point, PA


14 September 2004. Learning and memory in APP+PS1 transgenic mice. NIA-Johns Hopkins Conference on Assessing Cognition for Emerging Therapeutics in AD, Baltimore MD


14 October 2004. Immunotherapy for Alzheimer's Disease: Lessons from transgenic Mice. Sigma Xi Tampa Chapter, Tampa, FL


13 March 2005. Anti-Aß immunotherapy improves memory in aged app transgenic mice in spite of elevated vascular amyloid and microhemorrhage, 7th International Conference on AD/PD, Sorrento Italy


4 April 2005. Vaccination versus passive immunotherapy in the treatment of Alzheimer's. American Society for Pharmacology and Experimental Therapeutics Meeting.

San Diego, CA


12 April 2005. Immunotherapy for Alzheimer's disease. Lessons from transgenic mouse models

Florida Atlantic University, Boca Raton FL


8 June 2005. Immunotherapy as an approach to Alzheimer's disease. 9th International Conference on Neural Transplantation and Repair, Taipei, Taiwan.


28 June 2005. Microglial activation in APP transgenic mice after passive immunization with

anti-Aß antibodies. American Society for Neurochemistry, Madison WI


18 August 2005. Artifacts in immunoassays of anti-Aß antibody titers in serum. Talecris Inc. Research triangle Park, NC


10 November 2005. Immune Therapy for Alzheimer's Disease. National Parkinsons Foundation 9th International Symposium, Washington DC.


24 January 2006. Microglial activation in APP transgenic mice. Winter Conference on Brain Research, Steamboat Springs, CO.


7 April 2006. Amyloid Clearance in APP Transgenic Mice using Passive Immunization. National Institute on Aging Gerontology Research Center, Baltimore, MD


20 April 2006. Passive Immunotherapy in a Mouse Model of Amyloid Deposition. 9th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy. Geneva Switzerland.


4 May 2006. Modulating Microglia and Amyloid Clearance in APP Transgenic Mice. University of Cincinnati Neuroscience Program, Cincinnati OH.


15 May 2006. Immunotherapy against amyloid as a treatment for Alzheimer's disease: A therapeutic roller coaster. American Society for Neural Therapy and Repair Annual Meeting, Clearwater FL


16 May 2006. Update on Alzheimer's therapeutics. Patient Safety Research Center, Tampa FL


19 July 2006. Microglia Aging and Alzheimer’s Disease. 9th International Meeting on Alzheimer's Disease. Madrid Spain


7 September 2006. Immunotherapy, Vascular Amyloid and Microhemorrhage. Pfizer Inc, Groton CT


2 October 2006. Anti-Aß antibodies as a treatment for Alzheimer's disease. Karolinska Institute, Stockholm, Sweden


3 October 2006. Microglial activation and amyloid clearance using immunotherapy in transgenic mice. University of Uppsala, Uppsala Sweden


5 October 2006 Immunotherapy against Aß in a mouse model of amyloid deposition. AstraZeneca Symposium on Alzheimer's Disease. Sodertalje, Sweden


6 November 2006. Immunotherapy for Treatment of Alzheimer’s Disease. Southeastern Pharmacological Society Annual Meeting, Oxford, MS


10 January 2007 Immunotherapy for Alzheimer's Disease. Medical College of Georgia, Augusta GA


12 March 2007. Immunotherapy as a treatment for Alzheimer's disease, University of Zurich, Zurich Switzerland


19 March 2007. Increased vascular amyloid and microhemorrhage is observed with amyloid reductions caused by Aß vaccination but not nitro-NSAIDs. 8th International AD/PD Conference, Salzburg Austria


19 April, 2007. Immunotherapy for Alzheimer's disease. Conference on Alzheimer's Disease: From Molecular Mechanisms to Drug Discovery. Punta Cana, Dominican Republic


15 June 2007. Molecular Therapeutics for Alzheimer's. SRI International, Palo Alto, CA


26 June 2007 Antibodies for Alzheimer’s. From mouse models to clinical trials. Signature Program in Neuroscience Seminar, U South Florida, Tampa FL


29 Aug 2007. Immunotherapeutics for Alzheimer Disease. University of Maryland College of Pharmacy, Baltimore MD


8 September 2007. Gene therapy with Amyloid Degrading Proteases in Mouse Models of Amyloid Deposition. Symposium on Engineering Negligible Senescence. University of Cambridge, England


14 September 2007. Are APP transgenic mice good models of memory loss in Alzheimer's disease?. Alzheimer's Disease Research Symposium. AstraZeneca Pharmaceuticals, Sodertalje, Sweden


12 October 2007. Oligomeric Aß as a toxic agent in Alzheimer's Disease. Baxter Inc, Northbrook IL


16 January 2008. Immunotherapy to remove amyloid deposits. Potential as a therapeutic and usefulness as a research tool. University of Texas Health Sciences Center, San Antonio TX


6 February 2008. Immunotherapy for Alzheimer's disease". Columbia University College of Medicine. New York NY


18 February 2008. Therapeutic Reduction of Beta-Amyloid in Transgenic Mice. Sils Maria Conference, St Moritz, Switzerland


24 March, 2008. Antibody mediated clearance of amyloid deposits and restoration of memory. New York Academy of Science, New York, NY


27 July 2008. Microglial signal transduction mechanisms, Invited symposium presentation at International Congress on Alzheimer’s Dementia, Chicago IL.


28 July 2008. Passive Immunotherapies as an Approach to Disease Modification in Alzheimer’s Disease. Pfizer Educational Dinner Symposium, Chicago IL


26 August 2008. Immunotherapy as a treatment for Alzheimer’s disease. Federation of European Neurological Societies, Madrid Spain.


26 September 2008. Amyloid immunotherapy. Role of microglia/macrophages. University of Southern California, Los Angeles CA


7 November 2008. New Models of Drug Discovery Linking Academia and Industry. Presentation to Hampton Roads Chamber of Commerce,


21 November 2008. Immunotherapeutic approaches to lowering amyloid in AD. UK-US International Alzheimer’s Disease Symposium, Tampa FL


17 December, 2008. Development of Immunotherapy for Alzheimer's Disease. From Tribulations to Trials. University of Central Florida, Orlando FL


2 February 2009. Targetted Therapeis for Alzheimer’s Disease. Tampa Rotary Club, Tampa FL


27 February 2009, Molecular Therapeutic Approaches to  Lowering Brain Amyloid; Immunotherapy and Gene Therapy. University of Kentucky, Lexington KY


5 March 2009. Immunotherapy and Gene Therapy Against Brain Amyloid. Northwestern University, Chicago IL


14 March 2009. Modulating Aß with monocyte gene therapy. 9th International AD/PD Meeting, Prague, Czech Republic


26 March 2009. New Advances in Antibodies and Genes to Treat Alzheimer’s Disease. Museum of Science and Industry, Tampa FL


28 March 2009. Advances to treat Alzheimer’s Disease. Florida Elder Law Conference, Tampa FL


22 April 2009. Biomedical Ethics in the 21st Century. Moffitt Cancer Center, Tampa FL


10 June 2009 Molecular Approaches to Lowering Brain Amyloid; Immunotherapy and Gene Therapy. Linkoping Sweden


14 June 2009. Immunotherapy Against Aß as a Treatment for Alzheimer’s Disease. Conference on Neuroimmunology, Kuopio Finland


15 June 2009. Classical versus Alternative Activation of Microglia in Aging and Alzheimer’s Disease. Kuopio Finland


24 June 2009. Molecular Approaches to Lowering Brain Amyloid. Georgetown University, Washington DC


5 October 2009. new Developments in Alzheimer’s Disease. Exchange Club, Tampa FL


30 November 2009. Research Developments at the Byrd Alzheimer Institute, Rotary Club, Plant City FL


4 December 2009. Molecular Therapeutic for Alzheimer’s Disease . Third International Brain Conference. Orlando FL.


10 December 2009. Molecular Therapeutics for Alzheimer’s Disease. Texas A&M University. College Station TX.


11 February 2010. Aging and Alzheimer’s Disease. American Federation for Aging research Fundraiser. Miami FL


19 March 2010. Immunotherapeutic Approaches to Reducing Brain Amyloid. Alzheimer’s Research Trust Annual Meeting. Southampton, England

STUDENTS TRAINED

1   2   3   4

Похожие:

David g. Morgan, ph. D. 1 Jan 2009 iconContact: Jan Axelson, (608) 512-3729, jan@Lvr com

David g. Morgan, ph. D. 1 Jan 2009 icon[phys 585: Syllabus: Jan 19, 2009]

David g. Morgan, ph. D. 1 Jan 2009 iconНовости рынка розничных финансовых услуг
Совместное предприятие Morgan Stanley и Citigroup станет крупнейшей в США брокерской компанией – Morgan Stanley Smith Barney, управляющей...
David g. Morgan, ph. D. 1 Jan 2009 iconMorgan, M. Patrick. (2003)

David g. Morgan, ph. D. 1 Jan 2009 icon233 cis building 510 Morgan Circle

David g. Morgan, ph. D. 1 Jan 2009 iconThe Morgan Kaufmann Series in Data Management Systems

David g. Morgan, ph. D. 1 Jan 2009 iconBio: Acting Professor of Law, University of California, at Davis (King Hall) (). J. D., Ph. D. (Law and Society), New York University; B. A., Yale University. Thanks to Paul Chevigny, David Garland, Charles Reichmann, David Sklansky and Jerome Skolnick

David g. Morgan, ph. D. 1 Jan 2009 iconJ. D. Gibson et al. "Digital Compression for Multimedia: Principles and Standards," San Francisco, ca: Morgan Kaufmann, 1998."

David g. Morgan, ph. D. 1 Jan 2009 iconLatest references – as of jan 2012

David g. Morgan, ph. D. 1 Jan 2009 iconCurriculum vitae jan-Åke Gustafsson

Разместите кнопку на своём сайте:
Библиотека


База данных защищена авторским правом ©lib.znate.ru 2014
обратиться к администрации
Библиотека
Главная страница